Skip to main content
. Author manuscript; available in PMC: 2016 Jul 14.
Published in final edited form as: N Engl J Med. 2015 Nov 4;374(2):135–145. doi: 10.1056/NEJMoa1505917

Figure 2. Alterations in papillary renal cell carcinoma involving MET oncogene.

Figure 2

(a) Schematic of somatic mutations in MET, along with germline variant H1112R previously implicated in hereditary papillary renal cell carcinoma 37, and the novel RNA transcript variant of MET lacking the canonical exons 1 and 2, but containing a novel exon 1 that splices to the canonical exon 3. (b) Crystal structure for the MET tyrosine kinase catalytic domain (RCSB-PDB 3I5N38), on which are mapped the residues altered in papillary renal cell carcinoma. All amino acid numbering is based on the MET protein sequences.